

AC Collagen Prepeptide PF Toxicology Data

Code: 20452PF
INCI Name: Tripeptide-29
CAS #: 92113-31-0
EINECS #: 295-635-5

Name of Study	Type of Study	Results
Dermal and Ocular Irritation Test	<i>in-vitro</i>	Both the dermal and ocular assays reveal that AC Collagen Prepeptide PF is non-irritating.
Sirius Red Fast Green Report Analysis	<i>in-vitro</i>	AC Collagen Prepeptide PF exhibited positive collagen synthesis activity. The increase in collagen production may lead to improvement in the dermal-epidermal junction integrity as well as an improved scaffolding matrix.



Dermal and Ocular Irritation Tests

info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101

Tradename: AC Collagen Prepeptide PF

Code: 20452PF

CAS #: 92113-31-0

Test Request Form #: 408

Sponsor: Active Concepts, LLC; 107 Technology Drive Lincolnton, NC 28092

Study Director: Erica Segura

Principle Investigator: Meghan Darley

Test Performed:

In Vitro EpiDerm™ Dermal Irritation Test (EPI-200-SIT)

EpiOcular™ Eye Irritation Test (OCL-200-EIT)

SUMMARY

In vitro dermal and ocular irritation studies were conducted to evaluate whether **AC Collagen Prepeptide PF** would induce dermal or ocular irritation in the EpiDerm™ and EpiOcular™ model assays.

The product was tested according to the manufacture's protocol. The test article solution was found to be a **non-irritant**. Reconstructed human epidermis and cornea epithelial model were incubated in growth media overnight to allow for tissue equilibration after shipping from MatTek Corporation, Ashland, MA. Test substances were applied to the tissue inserts and incubated for 60 minutes for liquid and solid substances in the EpiDerm™ assay and 30 minutes for liquid substances and 90 minutes for solid substances in the EpiOcular™ assay at 37°C, 5% CO₂, and 95% relative humidity (RH). Tissue inserts were thoroughly washed and transferred to fresh plates with growth media. After post substance dosing incubation is complete, the cell viability test begins. Cell viability is measured by dehydrogenase conversion of MTT [(3-4,5-dimethyl thiazole 2-yl)], present in the cell mitochondria, into blue formazan salt that is measured after extraction from the tissue. The irritation potential of the test chemical is dictated by the reduction in tissue viability of exposed tissues compared to the negative control.

Under the conditions of this assay, the test article was considered to be **non-irritating**. The negative and positive controls performed as anticipated.

I. Introduction

A. Purpose

In vitro dermal and ocular irritation studies were conducted to evaluate whether a test article would induce dermal or ocular irritation in the EpiDerm™ and EpiOcular™ model assays. MatTek Corporation's reconstructed human epidermal and human ocular models are becoming a standard in determining the irritancy potential of test substances. They are able to discriminate between irritants and non-irritants. The EpiDerm™ assay has accuracy for the prediction of UN GHS R38 skin irritating and no-label (non-skin irritating) test substances. The EpiOcular™ assay can differentiate chemicals that have been classified as R36 or R41 from the EU classifications based on Dangerous Substances Directive (DSD) or between the UN GHS Cat 1 and Cat 2 classifications.

This information is presented in good faith but is not warranted as to accuracy of results. Also, freedom from patent infringement is not implied.
This information is offered solely for your investigation, verification, and consideration.



Dermal and Ocular Irritation Tests

info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101

II. Materials

- A. Incubation Conditions:** 37°C at 5% CO₂ and 95% relative humidity
- B. Equipment:** Forma humidified incubator, ESCO biosafety laminar flow hood, Synergy HT Microplate reader; Pipettes
- C. Media/Buffers:** DMEM based medium; DPBS; sterile deionized H₂O
- D. Preparation:** Pre-incubate (37°C) tissue inserts in assay medium; Place assay medium and MTT diluent at 4°C, MTT concentrate at -20°C, and record lot numbers of kit components
- E. Tissue Culture Plates:** Falcon flat bottom 96-well, 24-well, 12-well, and 6-well tissue culture plates
- F. Reagents:** MTT (1.0mg/mL); Extraction Solution (Isopropanol); SDS (5%); Methyl Acetate
- G. Other:** Nylon Mesh Circles (EPI-MESH); Cotton tip swabs; 1mL tuberculin syringes; Ted Pella micro-spatula; 220mL specimen containers; sterile disposable pipette tips; Parafilm

III. Test Assay

A. Test System

The reconstructed human epidermal model, EpiDerm™, and cornea epithelial model, EpiOcular™, consist of normal human-derived epidermal keratinocytes which have been cultured to form a multilayer, highly differentiated model of the human epidermis and cornea epithelium. These models consist of organized basal, spinous, and granular layers, and the EpiDerm™ systems also contains a multilayer stratum corneum containing intercellular lamellar lipid layers that the EpiOcular™ system is lacking. Both the EpiDerm™ and EpiOcular™ tissues are cultured on specially prepared cell culture inserts.

B. Negative Control

Sterile DPBS and sterile deionized water are used as negative controls for the EpiDerm™ and EpiOcular™ assays, respectfully.

C. Positive Control

Known dermal and eye irritants, 5% SDS solution and Methyl Acetate, were used as positive controls for the EpiDerm™ and EpiOcular™ assays, respectfully.

D. Data Interpretation Procedure

a. EpiDerm™

An irritant is predicted if the mean relative tissue viability of the 3 tissues exposed to the test substance is reduced by 50% of the mean viability of the negative controls and a non-irritant's viability is > 50%.

b. EpiOcular™

An irritant is predicted if the mean relative tissue viability of the 2 tissues exposed to the test substance is reduced by 60% of the mean viability of the negative controls and a non-irritant's viability is > 40%.

IV. Method

A. Tissue Conditioning

Upon MatTek kit arrival at Active Concepts, LLC the tissue inserts are removed from their shipping medium and transferred into fresh media and tissue culture plates and incubated at 37°C at 5% CO₂ and 95% relative humidity for 60 minutes. After those 60 minutes the inserts are transferred into fresh media and tissue culture plates and incubated at 37°C at 5% CO₂ and 95% relative humidity for an additional 18 to 21 hours.

This information is presented in good faith but is not warranted as to accuracy of results. Also, freedom from patent infringement is not implied.
This information is offered solely for your investigation, verification, and consideration.



Dermal and Ocular Irritation Tests

info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101

B. Test Substance Exposure

a. EpiDerm™

30µL (liquid) or 25mg (solid) of the undiluted test substance is applied to 3 tissue inserts and allowed to incubate for 60 minutes in a humidified incubator (37°C, 5% CO₂, 95% RH).

b. EpiOcular™

Each tissue is dosed with 20µL DPBS prior to test substance dosing. 50µL (liquid) or 50mg (solid) of the undiluted test substance is applied to 2 tissue inserts and allowed to incubate for 90 minutes in a humidified incubator (37°C, 5% CO₂, 95% RH).

C. Tissue Washing and Post Incubation

a. EpiDerm™

All tissue inserts are washed with DPBS, dried with cotton tipped swab, and transferred to fresh media and culture plates. After 24 hours the inserts are again transferred into fresh media and culture plates for an additional 18 to 20 hours.

b. EpiOcular™

Tissue inserts are washed with DPBS and immediately transferred into 5mL of assay medium for 12 to 14 minutes. After this soak the inserts are transferred into fresh media and tissue culture plates for 120 minutes for liquid substances and 18 hours for solid substances.

D. MTT Assay

Tissue inserts are transferred into 300µL MTT media in pre-filled plates and incubated for 3 hours at 37°C, 5% CO₂, and 95% RH. Inserts are then removed from the MTT medium and placed in 2mL of the extraction solution. The plate is sealed and incubated at room temperature in the dark for 24 hours. After extraction is complete the tissue inserts are pierced with forceps and 2 x 200µL aliquots of the blue formazan solution is transferred into a 96 well plate for Optical Density reading. The spectrophotometer reads the 96-well plate using a wavelength of 570 nm.

V. Acceptance Criterion

A. Negative Control

The results of this assay are acceptable if the mean negative control Optical Density (OD₅₇₀) is ≥ 1.0 and ≤ 2.5 (EpiDerm™) or ≥ 1.0 and ≤ 2.3 (EpiOcular™).

B. Positive Control

a. EpiDerm™

The assay meets the acceptance criterion if the mean viability of positive control tissues expressed as a % of the negative control is ≤ 20%.

b. EpiOcular™

The assay meets the acceptance criterion if the mean viability of positive control tissues is < 60% of control viability.

C. Standard Deviation

Since each irritancy potential is predicted from the mean viability of 3 tissues for EpiDerm™ and 2 tissues for EpiOcular™, the variability of the replicates should be < 18% for EpiDerm™ and < 20% EpiOcular™.



Dermal and Ocular Irritation Tests

info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101

VI. Results

A. Tissue Characteristics

The tissue inserts included in the MatTek EpiDerm™ and EpiOcular™ assay kits were in good condition, intact, and viable.

B. Tissue Viability Assay

The results are summarized in Figures 1 and 2. In no case was the tissue viability $\leq 50\%$ for EpiDerm™ or $\leq 60\%$ for EpiOcular™ in the presence of the test substance. The negative control mean exhibited acceptable relative tissue viability while the positive control exhibited substantial loss of tissue viability and cell death.

C. Test Validity

The data obtained from this study met criteria for a valid assay.

VII. Conclusion

Under the conditions of this assay, the test article substance was considered to be **non-irritating**. The negative and positive controls performed as anticipated.




Figure 1: EpiDerm tissue viability




Figure 2: EpiOcular tissue viability

This information is presented in good faith but is not warranted as to accuracy of results. Also, freedom from patent infringement is not implied. This information is offered solely for your investigation, verification, and consideration.



Sirius Red/Fast Green Collagen Analysis

info@activeconceptsllc.com • +1 (704)-276-7100 • Fax: +1 (704)-276-7101

Tradename: AC Collagen Prepeptide PF

Code: 20452PF

Lot #: 34715

CAS #: 92113-31-0

Test Request Form #: 946

Sponsor: *Active Concepts, LLC; 107 Technology Drive Lincolnton, NC 28092*

Study Director: *Erica Segura*

Principle Investigator: *Meghan Darley*

Test Performed:

Sirius Red/Fast Green Collagen Assay

Introduction

Collagen is the main protein of connective tissues, such as skin, bone, tendon and ligament, and the most abundant protein in mammals. Collagen accounts for nearly 25% to 35% of the total human protein content. Collagen is a long, fibrous protein that forms bundles called fibers giving structure and support to cells and tissues. Collagen has great tensile strength and is responsible for skin's elasticity and, therefore, its degradation leads to wrinkles that accompany aging.

Sirius Red/Fast Green Collagen Assay was conducted to assess the changes in collagen synthesis by **AC Collagen Prepeptide PF** treated *in vitro* cultured human dermal fibroblasts.

Assay Principle

Sirius Red is a unique dye that binds specifically to the helical structure of types I through V collagen, while Fast Green binds to non-collagenous proteins. These two dyes work in conjunction to provide a semi-quantitative method of determining amounts of collagen and non-collagenous proteins in a sample. After staining a sample the dyes are easily extracted and have optical density (OD) absorptions at 540nm (Sirius Red) and 605nm (Fast Green). Protein concentrations are calculated through equations with OD values.

This information is presented in good faith but is not warranted as to accuracy of results. Also, freedom from patent infringement is not implied.
This information is offered solely for your investigation, verification, and consideration.



Sirius Red/Fast Green Collagen Analysis

info@activeconceptsllc.com • +1 (704)-276-7100 • Fax: +1 (704)-276-7101

Materials

- A. **Kit:** Sirius Red/Fast Green Collagen Kit (Chondrex; 9046)
- B. **Incubation Conditions:** 37°C at 5% CO₂ and 95% Relative Humidity (RH)
- C. **Equipment:** Forma Humidified Incubator, ESCO Biosafety Laminar Flow Hood, Synergy HT Microplate Reader; Pipettes
- D. **Cell Line:** Normal Human Dermal Fibroblasts (Invitrogen; C-004-5C)
- E. **Media/Buffers:** Complete and Serum-Free Dulbecco's Modified Eagle Medium (DMEM); Phosphate Buffered Saline (PBS)
- F. **Culture Plate:** Falcon Flat Bottom 24-Well Tissue Culture Treated Plates
- G. **Reagents:** Ascorbic Acid-2-Glucose(AA2G) (100µM); Insulin Growth Factor-1 (IGF-1) (50ng/mL); Glacial Acetic Acid, Ethanol
- H. **Other:** Sterile Disposable Pipette Tips; Wash Bottles

Methods

Human dermal fibroblasts were seeded into 24-well tissue culture plates and allowed to grow to confluency in complete DMEM. 1%, 0.1%, and 0.01% concentrations of **AC Collagen Prepeptide PF** were added to the serum-free DMEM and incubated with fibroblasts for 24 hours. AA2G and IGF-1 were used as positive controls.

Media was removed from wells containing adherent fibroblasts and the cells were washed with PBS. 500µl of a cooled 95% ethanol/5% glacial acetic acid solution was added to the wells and incubated for 10 minutes at room temperature. 200µL of the Sirius Red/Fast Green dye solution was added to the fixed cell layer and incubated at room temperature for 30 minutes. The dye solution was removed from the cell layer and washed with water. 1mL of extraction solution was added for color extraction. The optical density was read at 540nm and 605nm on the Synergy HT Microplate Reader.

The protein concentrations of **AC Collagen Prepeptide PF** treated-fibroblasts were determined by calculations based on the optical density measurements and expressed in µg.

This information is presented in good faith but is not warranted as to accuracy of results. Also, freedom from patent infringement is not implied.
This information is offered solely for your investigation, verification, and consideration.

Results

The data obtained from this study met criteria for a valid assay and the positive and negative controls performed as anticipated.

AC Collagen Prepeptide PF elicited positive effects on collagen synthesis.

Collagen concentration is calculated by the following formula:

$$\text{Collagen } (\mu\text{g}) = \frac{[OD\ 540 - (OD\ 605 \times 0.291)]}{0.0378}$$

$$\text{Non Collagen Protein } (\mu\text{g}) = \frac{OD\ 605}{0.00204}$$




Figure 1: Collagen and non-collagen protein concentrations

This information is presented in good faith but is not warranted as to accuracy of results. Also, freedom from patent infringement is not implied. This information is offered solely for your investigation, verification, and consideration.




Figure 2: Percent collagen compared to non-collagen proteins

Discussion

As shown in figure 1, **AC Collagen Prepeptide PF** (code 20452PF) exhibited positive collagen synthesis activity. The increase in collagen production may lead to improvement in the dermal-epidermal junction integrity as well as an improved scaffolding matrix. For these reasons, we can assume **AC Collagen Prepeptide PF** (code 20452PF) is suitable for cosmetic applications designed to boost collagen synthesis to aid in providing a younger and healthier complexion.

This information is presented in good faith but is not warranted as to accuracy of results. Also, freedom from patent infringement is not implied. This information is offered solely for your investigation, verification, and consideration.